Collectively, these findings provide not only mechanistic insight into MC1R defense against αSyn pathologies but also therapeutic implications for the possible use of Nrf2 activators in PD patients, especially those carrying partial or complete loss-of-function MC1R variants. Here, NFE2L2 is linked to Parkinson disease.